1 Machine learning for predicting severe dengue, Puerto Rico

2

Zachary J. Madewell, PhD^{1,*}; Dania M. Rodriguez, PhD¹; Maile B. Thayer, PhD¹; Vanessa Rivera-Amill,
 PhD²; Gabriela Paz-Bailey, MD, PhD¹; Laura E. Adams, DVM¹; Joshua M. Wong, MD¹

PhD²; Gabriela Paz-Bailey, MD, PhD¹; Laura E. Adams, DVM¹; Joshua M. V

¹ Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico.
 ² Ponce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico.

8 9

* Correspondence to: Zachary J. Madewell, PhD; ock0@cdc.gov

10 Abstract

11	Background: Distinguishing between non-severe and severe dengue is crucial for timely intervention and
12	reducing morbidity and mortality. Traditional warning signs recommended by the World Health
13	Organization (WHO) offer a practical approach for clinicians but have limitations in sensitivity and
14	specificity. This study evaluates the performance of machine learning (ML) models compared to WHO-
15	recommended warning signs in predicting severe dengue among laboratory-confirmed cases in Puerto
16	Rico.
17	Methods: We analyzed data from Puerto Rico's Sentinel Enhanced Dengue Surveillance System (May
18	2012-August 2024), using 40 clinical, demographic, and laboratory variables. Nine ML models,
19	including Decision Trees, K-Nearest Neighbors, Naïve Bayes, Support Vector Machines, Artificial
20	Neural Networks, AdaBoost, CatBoost, LightGBM, and XGBoost, were trained using 5-fold cross-
21	validation and evaluated with area under the receiver operating characteristic curve (AUC-ROC),
22	sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A
23	subanalysis excluded hemoconcentration and leukopenia to assess performance in resource-limited
24	settings. An AUC-ROC value of 0.5 indicates no discriminative power, while a value closer to 1.0 reflects
25	better performance.
26	Results: Among the 1,708 laboratory-confirmed dengue cases, 24.3% were classified as severe. Gradient
27	boosting algorithms achieved the highest predictive performance, with AUC-ROC values exceeding 94%
28	for CatBoost, LightGBM, and XGBoost. Feature importance analysis identified hemoconcentration
29	(\geq 20% increase during illness or \geq 20% above baseline for age and sex), leukopenia (white blood cell
30	count <4,000/mm ³), and timing of presentation to a healthcare facility at 4–6 days post-symptom onset as
31	key predictors. Excluding hemoconcentration and leukopenia did not significantly affect model
32	performance. Individual warning signs like abdominal pain and restlessness had sensitivities of 79.0%
33	and 64.6%, but lower specificities of 48.4% and 59.1%, respectively. Combining \geq 3 warning signs
34	improved specificity (80.9%) while maintaining moderate sensitivity (78.6%), resulting in an AUC-ROC
35	of 74.0%.

- 36 **Conclusions:** ML models, especially gradient boosting algorithms, outperformed traditional warning
- 37 signs in predicting severe dengue. Integrating these models into clinical decision-support tools could help
- 38 clinicians better identify high-risk patients, guiding timely interventions like hospitalization, closer
- 39 monitoring, or the administration of intravenous fluids. The subanalysis excluding hemoconcentration
- 40 confirmed the models' applicability in resource-limited settings, where access to laboratory data may be
- 41 limited.
- 42 Keywords: ensemble learning, gradient boosting, feature importance, clinical decision support,
- 43 Caribbean

44 Background

45 Dengue is a significant public health concern worldwide, with approximately 390 million infections annually, of which 96 million manifest clinically [1, 2]. In Puerto Rico, dengue has been 46 47 associated with nearly 30,000 confirmed and probable cases from 2010 to 2020, including 584 severe 48 cases, 10,000 hospitalizations, and 68 deaths [3]. A surge in dengue cases on the island in 2024 prompted 49 a public health emergency declaration by Puerto Rico's Department of Health, highlighting the ongoing 50 threat of dengue to the island [4]. These regular outbreaks strain healthcare resources and pose substantial 51 morbidity and mortality risks. A critical aspect of managing dengue is distinguishing between non-severe 52 and severe cases, as the latter require intensive medical intervention to prevent complications and 53 fatalities. Early identification of patients at risk of severe dengue is important for timely intervention and 54 improved patient outcomes. However, predicting which patients will progress to severe dengue remains a 55 challenge, often leading to delayed treatment and increased healthcare burden. 56 The World Health Organization (WHO) has recommended identifying severe dengue through 57 clinical assessment of warning signs such as persistent vomiting, abdominal pain, mucosal bleeding, 58 restlessness, and hepatomegaly [5]. Although these warning signs offer a practical approach for clinicians, 59 their specificity and sensitivity in accurately predicting severe dengue are limited. Studies have shown 60 that relying solely on these warning signs can result in both false positives and negatives, potentially 61 leading to over- or under-treatment of patients [6-10]. The substantial burden of dengue on the healthcare 62 system, both in terms of economic cost and human suffering, underscores the need for innovative 63 approaches to disease diagnosis. A more accurate and efficient method for risk stratification could lead to 64 substantial improvements in patient care and resource allocation. 65 In recent years, machine learning (ML) has emerged as a powerful tool for analyzing complex datasets and uncovering patterns not easily discernible by traditional methods. In the context of dengue, 66 67 ML models can analyze a multitude of factors beyond the established warning signs, including patient 68 demographics, laboratory results, clinical symptoms, and epidemiological data, to enhance the prediction

69 of severe disease [11, 12]. By leveraging ML, we aim to improve the accuracy of severe dengue

predictions, offering a more robust and data-driven approach to risk stratification. If successful, these models could transform dengue management by enabling early, accurate identification of high-risk patients, ultimately leading to improved patient outcomes and reduced mortality rates. Additionally, targeted intervention for high-risk patients can optimize resource allocation, ensuring critical care is available to those who need it most.

75 This project specifically leverages data from Puerto Rico's Sentinel Enhanced Dengue 76 Surveillance System (SEDSS), which has detailed clinical and laboratory information on dengue cases, 77 allowing for the exploration of potential predictors of disease severity beyond the conventional warning 78 signs. In addition to exploring ML approaches, this project also aims to evaluate the performance of 79 WHO-recommended warning signs in predicting severe dengue among laboratory-confirmed cases, 80 which include both molecular (RT-PCR) and serologic (IgM ELISA) testing. By doing so, we seek to 81 bridge the gap between research and clinical practice by demonstrating the practical applications of both 82 traditional and advanced computational tools in identifying severe dengue. If our findings demonstrate 83 that ML models offer improved prediction of severe dengue compared to traditional methods, this could 84 highlight the potential for integrating advanced computational tools into public health strategies and 85 clinical protocols. For example, predictive ML models could be incorporated into clinical decision 86 support systems used in emergency departments or outpatient clinics, enabling real-time risk stratification 87 for severe dengue. This integration could help healthcare providers prioritize patients for hospitalization, 88 allocate medical resources more efficiently, and guide timely interventions to prevent complications and 89 fatalities. These tools could enable early and accurate identification of high-risk patients, improve patient 90 outcomes, and optimize resource allocation.

91

92 Methods

93 *Study population*

In this analysis, we used data from SEDSS, an ongoing facility-based study in Puerto Rico that
tracks the frequency and causes of acute febrile illness [13, 14]. Our study included data from SEDSS

96	from May 2012 to August 2024. SEDSS has included five sites: 1) Centro Médico Episcopal San Lucas
97	(CMESL) in Ponce, a tertiary acute care facility (2012-present), 2) Hospital Episcopal San Lucas (HESL)
98	- Guayama, a secondary acute care hospital (2013–2015), 3) Hospital de La Universidad de Puerto Rico
99	in Carolina, another secondary acute care teaching hospital (2013–2015), 4) Centro de Emergencia y
100	Medicina Integrada (CEMI), an outpatient acute care clinic in Ponce (2016-present), and 5) Auxilio
101	Mutuo Hospital, a tertiary care facility in the San Juan Metro Area (2018-present).
102	
103	Study enrollment and data collection
104	SEDSS enrolls participants using convenience sampling. Potential participants are identified by
105	triage nurses as any patient with an acute febrile illness (AFI) defined by the presence of fever (\geq 38.0°C
106	for temperatures measured orally, \geq 37.5°C for temperatures measured rectally, and \geq 38.5°C for
107	temperatures measured axillarily for both children and adults) at the time of triage or chief complaint of
108	having a fever within the past seven days. During the Zika virus epidemic in Puerto Rico (June 2016-
109	June 2018), patients were eligible if they presented with either rash and conjunctivitis, rash and arthralgia,
110	or fever [15]. Starting in April 2020, patients with cough or dyspnea within the last 14 days (with or
111	without fever) were also eligible to better capture respiratory viruses [16]. No age groups were excluded,
112	although infants were only eligible for enrollment if they presented to the hospital after their initial
113	discharge after birth. After meeting the inclusion criteria and being informed about the study, participants
114	provided written informed consent. In cases where patients were incapacitated at the time of triage due to
115	acute illness, consent was sought after their stabilization.
116	SEDSS collects data via patient interviews and medical record reviews at enrollment and
117	convalescence (~7-14 days later). The case investigation form (CIF) gathers information about patient
118	demographics, comorbidities, and clinical features. The convalescent sample processing form (CSPF)
119	echoes CIF data, adding the second specimen collection date and AFI severity indicators
120	(hospitalizations, clinic visits). Inpatient medical data for participants with AFIs who were admitted to the
121	hospital from CMESL, HESL-Guayama, and Auxilio Mutuo Hospital also were collected using a separate

122 form (Hospital Admitted Abstraction Form) to collect key clinical indicators of disease severity and 123 progression. For admitted patients, these data included information on extent and nature of hemorrhage, 124 plasma leakage (e.g., ascites and pleural and cardiac effusions), hematologic indicators of increased 125 intravascular permeability (e.g., hematocrit and serum albumin levels), additional blood pressure and 126 heart rate measures to assess shock, and indicators of severe organ involvement (e.g., liver impairment, 127 meningitis, and encephalitis) [14]. 128 Dengue warning signs and severe dengue were defined by the World Health Organization [17], 129 incorporating available clinical indicators from SEDSS intake and follow-up forms and abstracted 130 inpatient medical records. Dengue warning signs were defined by abdominal pain or tenderness, 131 persistent vomiting, plasma leakage (pleural or pericardial effusion or ascites), mucosal bleeding, 132 restlessness, hemoconcentration (defined as either a hematocrit increase of $\geq 20\%$ during illness or a 133 hematocrit value $\geq 20\%$ above baseline for age and sex), or hepatomegaly. Detailed definitions for these

variables have been provided previously [18]. Severe dengue was defined as severe plasma leakage or

shock, severe bleeding, or severe organ impairment [18]. The presence and overlap of warning signs

among severe dengue cases were visualized using an Euler plot via the eulerr R package [19].

137

138 Sample collection and laboratory procedures

Blood, nasopharyngeal (NP), and oropharyngeal (OP) specimens were collected at enrollment from eligible participants. Additional blood samples (serum and whole blood) were also collected during the convalescent phase. Participation required providing at least one sample (blood or OP/NP swab). All patients had molecular testing for dengue virus for specimens collected within 7 days of symptom onset. Serologic testing was done by Immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay (ELISA) for anti-DENV antibodies for specimens collected >3 days after symptom onset [20].

146 Variables

147 A total of 40 variables were selected based on the WHO's criteria for severe dengue, physicians' 148 clinical experience, and a review of current literature to potentially differentiate between severe and non-149 severe dengue cases [17, 18, 21-24]. These features included age group, days post onset of symptoms, 150 clinical signs and symptoms, laboratory findings, pre-existing health conditions, and dengue virus 151 serotype. Clinical symptoms included report of fever, rash, headache, myalgia, abdominal pain, chills, 152 itchy skin, eye pain, nasal discharge, cough, sore throat, persistent vomiting, diarrhea, arthralgia, arthritis, 153 back pain, calf pain, nausea, no appetite, and restlessness. Clinical signs, as observed by healthcare 154 providers, included objective fever at the time of enrollment, vellow skin (jaundice), observed bruising, 155 conjunctivitis, hepatomegaly, mucosal bleeding, pale skin, and blue lips (cyanosis). Clinical laboratory 156 findings comprised leukopenia (defined as white blood cell count <4,000/mm³), the calculated value of 157 hemoconcentration (an increase in the concentration of red blood cells due to plasma loss), and dengue 158 immune status (primary or post-primary) as measured from results for anti-dengue virus immunoglobulin 159 G (IgG) on or before day 5 of illness. Pre-existing health conditions like obesity (BMI \geq 30), gastritis, 160 chronic arthritis, hypertension, chronic kidney disease, diabetes, thyroid disease, and high cholesterol were also considered. Additionally, dengue virus serotype was included, coded as "unknown" for 161 162 probable cases identified through IgM ELISA, as serotype data was only available for confirmed reverse transcription polymerase chain reaction (RT-PCR) cases. Thrombocytopenia and clinical fluid 163 164 accumulation were excluded from the analysis, as they generally manifest after the onset of severe disease 165 or are components of its definition, making them less useful as predictive features. This comprehensive 166 set of variables was intended to represent the multifaceted nature of factors influencing dengue infection 167 severity. 168

169 Sensitivity analyses

To further explore the performance of the models in resource-constrained settings, where
complete blood counts (CBCs), dengue immune status, and serotype information might not be readily
available, we performed sub-analyses to evaluate model robustness and applicability. The sub-analyses

173 included: 1) excluding results found on a CBC (i.e., leukopenia and hemoconcentration), 2) excluding 174 IgG and serotype results, and 3) excluding leukopenia, hemoconcentration, IgG, and serotype results. 175 These analyses were designed to assess how well the models could predict progression to severe dengue 176 in various clinical scenarios, particularly where access to comprehensive clinical laboratory results or 177 pathogen-specific testing might be limited. 178 To ensure the robustness of our models and account for potential confounding from co-circulating 179 arboviruses, we performed a sensitivity analysis with the highest-performing individual ML model, 180 excluding cases that tested positive for chikungunya virus (CHIKV) by either IgM or RT-PCR. This 181 analysis aimed to confirm that the predictive features for severe dengue remain consistent even in the 182 absence of CHIKV, given the potential overlap in clinical presentations between the two viruses. 183 184 Sampling 185 Our analysis included laboratory-confirmed dengue cases, confirmed by either molecular or 186 serologic testing, focusing on differentiating between severe and non-severe cases. Due to an imbalance 187 in the dataset, where non-severe cases were more prevalent, we used upsampling to balance the class 188 distribution. Upsampling involves increasing the number of minority class samples (severe dengue cases) 189 through duplication, which helps to prevent model bias towards the majority class and improves the 190 model's ability to accurately predict severe dengue cases [25]. Upsampling was done using the upSample 191 function from the caret package in R [26]. Following upsampling, the dataset was divided into training 192 and testing sets using a 70/30 split: 70% of the data was allocated for training the models, while the 193 remaining 30% was reserved for testing. This partitioning ensured that the models were trained on a 194 substantial portion of the data while retaining a sufficient amount for unbiased evaluation. 195 196 Machine learning models 197 An initial logistic regression (LR) model served as a baseline simple model to explore the

198 relationship between potential predictors and the outcome of severe dengue. Stepwise selection,

199 implemented using the stepAIC function from the MASS package in R [27], was used to iteratively add 200 or remove variables to identify the optimal model with the lowest Akaike Information Criterion. This 201 approach balances model complexity and goodness-of-fit by selecting variables that contribute 202 significantly to the model. The final logistic regression model, derived from stepwise selection, was 203 evaluated on both the training and testing sets. 204 In addition, we used nine ML methods to predict severe dengue and analyze feature importance. 205 A comprehensive selection of models was used to leverage different strengths, enhance predictive 206 performance, and provide a nuanced understanding of the factors contributing to severe dengue. The 207 algorithms used include Decision Trees (DT), K-Nearest Neighbors (KNN), Naïve Bayes, Support Vector 208 Machines (SVM), Artificial Neural Networks (ANN), Adaptive Boosting (AdaBoost), Categorical 209 Boosting (CatBoost), Light Gradient Boosting Machine (LightGBM), and eXtreme Gradient Boosting 210 (XGBoost). DTs create a tree-like structure to make predictions by recursively splitting the data based on 211 feature values [28]. KNNs predict the class of a data point by considering the majority class of its closest

neighbors in the feature space [29]. Naïve Bayes is a probabilistic classifier that applies Bayes' theorem,

assuming independence between predictors [30]. SVMs identify the optimal hyperplane to separate

classes, making them effective for high-dimensional data [31]. ANNs are inspired by biological neural

215 networks and consist of interconnected nodes that can capture complex patterns [32]. AdaBoost,

216 CatBoost, LightGBM, and XGBoost are ensemble methods that combine multiple weak learners to

217 improve predictive performance [33, 34]. AdaBoost adjusts weights to focus on difficult-to-predict

218 instances, CatBoost handles categorical features effectively, LightGBM is efficient with large datasets

due to its leaf-wise tree growth, and XGBoost uses regularization techniques to prevent overfitting,

enhancing accuracy and robustness [33-35].

The hyperparameters (model-specific settings, such as learning rate, maximum tree depth, or number of estimators) for each ML model were carefully tuned using a grid search strategy to optimize performance. The area under the receiver operating characteristic curve (AUC-ROC) was used as the optimization metric, ensuring a focus on maximizing classification performance. We used 5-fold cross-

225 validation during model training to enhance robustness and mitigate overfitting. Specific details of the grid search strategy and parameters included in each model are provided in Table S1. 226 227 The following R packages were used for model implementation: rpart [36] for DT, e1071 [37] for 228 Naïve Bayes and SVM, caret [26] for KNN, nnet [38] for ANN, keras [39] for DNN, ada [40] for 229 AdaBoost, catboost [41] for CatBoost, lightgbm [42] for LightGBM, and xgboost [43] for XGBoost. All 230 analyses were done using R version 4.4.0 [44]. 231 232 Ensemble model 233 To leverage the predictive power of multiple ML algorithms, we used an ensemble learning 234 approach with a stacked generalization framework. This method combines the strengths of various 235 individual models to improve overall predictive performance and robustness. We used predictions from 236 LR and the nine different ML models as base learners in our ensemble. Specifically, we used a logistic 237 regression model as the meta-learner to combine the outputs of the base models. This approach allows the 238 meta-model to learn the optimal combination of base models' predictions. To improve the performance of the meta-model, we again used stepwise selection with the stepAIC function from the MASS package 239 240 [27]. 241 Pearson correlation coefficients were calculated to measure the linear correlation between the 242 predictions of the ML models. This analysis helps determine whether the models are making similar 243 predictions for severe dengue, potentially reflecting the selection of similar variables and patterns across 244 the models. The results were visualized in a heatmap using ggplot2 [45]. 245 246 Performance evaluation 247 Model performance for each ML model and the meta-model was evaluated on both the training 248 and testing sets using AUC-ROC as the primary performance metric. AUC-ROC is an aggregate measure 249 of performance across all possible classification thresholds, providing a comprehensive assessment of the

250 model's ability to distinguish between classes. We used the DeLong method to calculate the confidence 251 intervals for the AUC-ROC to ensure accurate estimation of the model's performance [46]. 252 The performance of the ensemble model was further evaluated using several metrics, including 253 accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1 254 score, and Cohen's kappa. These metrics provide a comprehensive view of the model's performance, 255 capturing both the ability to correctly classify severe dengue cases and the overall agreement between 256 predicted and actual classifications. 257 258 *Feature importance* 259 Feature importance was calculated for each ML model to quantify the contribution of each 260 variable to the model's predictive accuracy. This approach enables the identification of the most 261 influential features, which enhances our understanding of the factors driving the predictions for severe 262 dengue. Feature importance was assessed for both the 40-variable feature set and a subset excluding

263 CBCs, IgG, and serotype results. Different methods were applied across the ML algorithms to determine

264 feature importance. For ensemble-based methods, including XGBoost, LightGBM, and CatBoost, feature

265 importance was calculated using the Gain metric, which measures the contribution of each feature to the

266 model's decision-making process. Gain represents the improvement in the model's accuracy brought by a

267 feature, with higher values indicating greater importance. For XGBoost, LightGBM, and CatBoost, we

used the xgb.importance, lgb.importance, and catboost.get_feature_importance functions from the

xgboost [43], lightgbm [42], and catboost [41] packages, respectively.

Permutation importance was applied to assess feature importance for KNN, Naive Bayes, and ANN. This method involves randomly shuffling feature values and measuring the subsequent decline in model performance. A substantial decrease in accuracy indicates a highly influential feature. For DT, feature importance was determined by the reduction in impurity (Gini index or entropy) achieved by splitting data based on that feature. AdaBoost assigned importance to features based on their contribution to correcting errors in subsequent models, with higher weights indicating greater influence. For SVM,

276 feature importance was derived from the absolute value of the model coefficients. The magnitude of these
277 coefficients reflects the influence of each feature on the decision boundary, with larger coefficients
278 indicating greater importance.

279 We also calculated and plotted SHapley Additive exPlanations (SHAP) values for the top three 280 performing models based on AUC-ROC. SHAP values provide a nuanced measure of each feature's 281 contribution to the prediction of severe dengue cases, enabling a deeper understanding of model decision-282 making. Positive SHAP values indicate a higher likelihood of severe dengue, whereas negative values 283 suggest a protective effect. The SHAP approach is particularly valuable as it allows for the decomposition 284 of the prediction into individual feature contributions, offering a clear interpretation of how different 285 variables influence the model's predictions. 286 287 Post-hoc variable reduction analysis

To assess the predictive performance of a simplified variable set, we conducted a post-hoc analysis using the ML model that achieved the highest AUC. This analysis aimed to identify the minimum number of features needed to maintain high accuracy. We began with the top features identified through SHAP values in the original 40-variable analysis, adding one feature at a time, starting with the highest-ranking. At each step, we evaluated the AUC-ROC to determine the impact of including additional features. The goal was to develop a more streamlined model that remains feasible and interpretable, especially in clinical settings with limited diagnostic resource.

295

296 Diagnostic accuracy of warning signs

In addition to ML, we evaluated the diagnostic accuracy of individual warning signs for identifying severe dengue cases. The performance of each warning sign was assessed using sensitivity, specificity, PPV, NPV, and AUC-ROC. Sub-analyses assessed the performance of warning signs by dengue serotype and immune status. Dengue serotype was determined via RT-PCR, whereas immune status was classified based on IgG antibody results in the first 5 days after illness onset (primary: IgG;

302	post-primary: positive IgG). Cases lacking serotype or immune status data were excluded from sub-
303	analyses. This approach aimed to identify potential clinical differences in the presentation and predictive
304	capacity of warning signs for severe dengue across serotypes and infection statuses.
305	
306	Ethics statement
307	The Institutional Review Boards at the Centers for Disease Control and Prevention (CDC),
308	Auxilio Mutuo, and Ponce Medical School Foundation approved the SEDSS study protocols 6214, and
309	120308-VR/2311173707, respectively. Written consent to participate was obtained from all adult
310	participants and emancipated minors. For minors aged 14 to 20 years, written consent was obtained, and
311	for those aged 7 to 13 years, parental written consent and participant assent were obtained.
312	
313	Results
314	Characteristics of dengue cases
315	From May 2012 to August 2024, there were 51,877 unique AFI visits from 41,647 participants
316	enrolled in SEDSS, including 8,404 hospitalizations or transfers and 75 deaths. Of these visits, there were
317	50,189 AFI visits from 40,495 participants tested for DENV. From these, 1,708 (3.4%) had dengue (1,218
318	confirmed, 490 probable). The majority of the 1,206 serotyped dengue cases were DENV-1 (n=905,
319	75.0%), followed by DENV-3 (n=149, 12.4%), DENV-2 (n=102, 8.5%), and DENV-4 (n=50, 4.1%). Of
320	1,708 dengue cases, 759 (44.4%) were hospitalized or transferred, and two (0.1%) died. The median
321	duration from symptom onset to presentation at the emergency room was 3 days [IQR: 2, 5]. Of the 730
322	participants assessed for immune status using DENV IgG, 577 (79.0%) were positive, indicating post-
323	primary dengue, whereas the remaining 153 (21.0%) were negative, suggesting primary dengue
324	infections.
325	Among the 1,708 laboratory-confirmed dengue cases, 24.3% (n=415) were classified as severe
326	dengue. Compared to those without severe dengue, participants with severe dengue were more likely to
327	present between 4 to 6 days post-symptom onset (52.4% vs. 32.0%, $p < 0.001$) and be aged 10-19 years

14

328	(51.6% vs. 36.3%, $p < 0.001$) (Table 1). Among dengue cases tested, a higher proportion of severe cases
329	were post-primary DENV infections (85.7% vs. 76.3%, $p = 0.007$). Participants with severe dengue had a
330	higher prevalence of warning signs such as persistent vomiting (37.6% vs. 20.4%), abdominal pain
331	(79.0% vs. 51.6%), restlessness (64.6% vs. 40.9%), mucosal bleeding (22.9% vs. 13.8%), and
332	hemoconcentration (20.7% vs. 3.3%) compared to lab-confirmed non-severe cases (all $p < 0.001$) (Figure
333	1). All 30 dengue cases with seizures were classified as severe dengue. Leukopenia (77.1% vs. 53.5%)
334	was more prevalent among participants with severe dengue ($p < 0.001$).
335	
336	Performance of warning signs for predicting severe dengue
337	Among warning signs, abdominal pain and restlessness had the highest sensitivities for predicting
338	severe dengue at 79.0% and 64.6%, respectively, but the lowest specificities of 48.4% and 59.1% (Table
339	2). In contrast, hepatomegaly and hemoconcentration demonstrated the highest specificities at 97.8% and
340	96.7%, respectively, but were less sensitive at 4.6% and 20.7%, respectively. The presence of any
341	warning sign yielded the highest sensitivity (92.8%) but a low specificity (29.2%), with an AUC-ROC of
342	61.1%. Combining three or more warning signs increased the specificity to 65.1% while maintaining
343	moderate sensitivity (87.2%), resulting in the highest AUC-ROC (71.3%) among the combinations tested.
344	Performance of warning signs for predicting severe dengue demonstrated some variability across
345	serotypes and immune status, though the interpretation is constrained by limited sample sizes and
346	overlapping confidence intervals (Tables S2-S3).
347	
348	Performance evaluation of machine learning models
349	The ensemble model demonstrated a strong correlation between predictions from the CatBoost,
350	XGBoost, LightGBM, and AdaBoost models, with Pearson correlation coefficients of 0.91, 0.89, 0.89,
351	and 0.84, respectively, indicating that these gradient boosting models had substantial influence on the

- ensemble's predictions (Figure 2). This high correlation suggests that the models may be selecting and
- 353 emphasizing similar variables in their predictive processes. In contrast, weaker correlations were observed

354	between the ensemble model and simpler models like KNN (0.48), Naïve Bayes (0.48), and DT (0.51),
355	indicating different prediction patterns and potential differences in variable selection. Additionally, high
356	inter-model correlations among gradient boosting models, particularly between LightGBM and XGBoost
357	(0.98), further support the idea that these models capture similar patterns in the data and rely on
358	comparable sets of variables.
359	AUC values for the 40-variable feature set across various ML models demonstrated varying
360	levels of predictive performance. Gradient boosting algorithms achieved the highest AUC values of
361	97.1% for CatBoost, 95.5% for XGBoost, and 94.5% for LightGBM, indicating strong discriminatory
362	power (Figure 3). ANN showed moderate performance (AUC = 88.4%), whereas LR and SVM had lower
363	discrimination (AUC = 79.4% and 78.9%, respectively). KNN, Naïve Bayes, and DT had the lowest AUC
364	values of 74.1%, 75.9%, and 76.2%, respectively, indicating limited predictive ability. The ensemble
365	meta-model provided a slight improvement over CatBoost with an AUC of 97.7%.
366	Exclusion of immune status and serotype data minimally affected model performance across all
367	ML algorithms (Figure 3). Conversely, removing leukopenia and hemoconcentration significantly
368	reduced predictive power for Naïve Bayes, LR, SVM, and ANN (AUC decreased by 3.2% ~ 5.2%).
369	CatBoost, XGBoost, LightGBM, and the ensemble model consistently maintained high performance,
370	showing minimal to no change in AUC, regardless of the inclusion or exclusion of leukopenia and
371	hemoconcentration. Excluding CHIKV-positive cases in the sensitivity analysis resulted in minimal
372	changes to the AUC-ROC scores for CatBoost, confirming that the model's predictive performance for
373	severe dengue remains robust even in the presence of co-circulating arboviruses (Table S4).
374	The ensemble model with 40 variables achieved the highest overall AUC of 97.7% with
375	corresponding sensitivity and specificity of 95.6% and 93.3%, respectively (Table S5). The F1 score was
376	94.5% and Kappa was 88.9%, indicating a high level of agreement and balanced performance between
377	precision and recall in the model's classification of severe dengue cases.
378	

Feature importance

380	For the 40-variable feature set, SHAP values identified hemoconcentration, days post symptom
381	onset, and leukopenia as most important features for CatBoost, XGBoost, and LightGBM (Figure 4,
382	Figures S1-S2). Similarly, LR highlighted these variables as having the highest adjusted odds ratios for
383	severe dengue (hemoconcentration: aOR 7.02; leukopenia: aOR 2.24; days post onset 4-6 days: aOR
384	1.96) (Table S6). Additionally, these models highlighted pale skin, age group, and the clinical warning
385	signs of restlessness, abdominal pain, and persistent vomiting as key predictors of severe dengue
386	progression. Hemoconcentration also stood out as a top feature for Naïve Bayes and SVM (Figure S3-S4).
387	AdaBoost, which focuses on correcting errors from previous classifiers, assigned greater importance to
388	chronic conditions such as high cholesterol, chronic arthritis, and hypertension. Although hepatomegaly is
389	a recognized warning sign, it had a lower importance score in our analysis, suggesting it may play a more
390	limited role in predicting severe dengue in this context.
391	
392	Post-hoc variable reduction analysis
393	To explore a more streamlined predictive model, we conducted a post-hoc variable reduction
394	analysis using the ML model with the highest AUC, CatBoost. Starting with the top feature identified by
395	SHAP values (days post onset), we sequentially added variables, assessing AUC-ROC at each step. The
396	AUC improved consistently with each additional variable, though the gains diminished over time. By
397	including just 20 variables—compared to the original 40-variable set—the model achieved an AUC of
398	96.5% (Figure 5). The optimal reduced feature set included days post onset, hemoconcentration,
399	leukopenia, restlessness, pale skin, abdominal pain, age group, diarrhea, rash, persistent vomiting, cough,
400	calf pain, sore throat, arthralgia, itchy skin, eye pain, back pain, mucosal bleeding, myalgia, and arthritis.
401	This reduced model offers a more practical and interpretable approach while maintaining high predictive
402	accuracy, making it feasible for use in clinical settings, especially where diagnostic resources are limited.
102	

404 Discussion

405 Our study underscores the potential of ML models, particularly gradient boosting algorithms, to 406 outperform traditional warning signs in predicting severe dengue. This improved predictive ability could 407 transform clinical decision-making, enabling earlier and more accurate identification of high-risk patients, 408 thereby improving outcomes in dengue-endemic regions like Puerto Rico. 409 Hemoconcentration, days post symptom onset, and leukopenia emerged as the most important 410 features across multiple ML models, aligning with their known relevance in dengue prognosis [47-49]. 411 Hemoconcentration, which reflects plasma leakage through an increased red blood cell concentration, was 412 consistently highlighted as a top predictor by CatBoost, XGBoost, LightGBM, and several other 413 algorithms. Days post symptom onset is a crucial temporal marker, likely capturing the dynamic nature of 414 disease as cases often progress to the critical phase of dengue (when severe disease occurs) 3–7 days after 415 symptom onset. Leukopenia, or low white blood cell count, often reflects the body's response to viral 416 infections, including dengue. In addition, pale skin, age group, and clinical warning signs such as 417 restlessness, abdominal pain, and persistent vomiting were identified as key predictors of severe dengue 418 progression. The variability in feature importance across models emphasizes the complexity of severe 419 dengue prediction, highlighting the need for tailored approaches that account for both individual patient

420 characteristics and disease progression.

Our analysis highlights the strong predictive performance of gradient boosting algorithms— 421 422 CatBoost, XGBoost, and LightGBM—with AUC values above 94%, reflecting their ability to capture 423 complex, non-linear patterns in clinical data [35, 50-52]. Despite this high predictive accuracy, the 424 interpretability of these models remains a limitation in clinical settings, where transparency in decision-425 making is critical for trust and practical use [53-55]. Compared to simpler models like LR, which offers 426 straightforward interpretations of how each variable influences severe dengue risk, gradient boosting 427 algorithms can be challenging to interpret. This trade-off between high performance and interpretability 428 suggests that ML models may be most useful as supplementary tools for alerting clinicians to high-risk 429 cases, rather than as standalone decision aids.

430 In contrast, simpler models like Naïve Bayes, Decision Trees, and KNN showed weaker 431 correlations and lower AUC values, reflecting their limitations in capturing data complexity. The 432 ensemble model, achieving the highest AUC of 97.7%, demonstrates the added value of combining 433 multiple ML algorithms to enhance predictive accuracy, with high sensitivity and specificity, making it 434 particularly useful in resource-limited settings [56, 57]. Additionally, the exclusion of immune status and 435 serotype data had minimal impact on model performance, indicating these variables are not essential for 436 accurate prediction in this context. The high NPV across models suggests that ML tools can still be 437 valuable for identifying low-risk patients who may not require intensive monitoring. In these cases, the 438 ML model's recommendation could serve as an early discharge or outpatient management decision-439 support mechanism, further optimizing healthcare resource allocation. 440 The post-hoc variable reduction analysis demonstrated that a streamlined set of 20 variables 441 achieved strong predictive accuracy (AUC of 96.5%), close to the full 40-variable model. This reduced 442 set offers a balance between interpretability and performance, making it more practical for clinical 443 application, particularly in settings with limited diagnostic resources. By focusing on essential 444 predictors—such as hemoconcentration, days post onset, leukopenia, and key symptoms—this approach 445 prioritizes feasibility and interpretability, even if it means a modest sacrifice in predictive power. For 446 added clinical utility, LR could complement ML approaches by further refining and validating the 447 reduced variable set with interpretable odds ratios, enabling clinicians to apply these findings more 448 confidently in practice [58]. 449 Traditional warning signs showed both strengths and limitations. Abdominal pain and restlessness

450 were the most sensitive indicators, consistent with other studies [6, 9], yet their low specificities limit 451 their utility. Conversely, markers like hepatomegaly and hemoconcentration had high specificity but low 452 sensitivity. Combining multiple warning signs improved specificity while maintaining high sensitivity, 453 yielding the highest AUC among tested combinations. In contrast, gradient boosting ML algorithms 454 offered a more balanced approach with high sensitivity and specificity, crucial for accurate risk 455 stratification in clinical settings. Our findings align with a recent study where an 8-gene XGBoost model

456 outperformed clinical warning signs, significantly improving negative predictive power and 457 demonstrating strong generalizability across patient cohorts [54]. Although our models focus on 458 demographic and clinical features, the integration of gene expression data presents an intriguing avenue 459 for future exploration [54, 55]. 460 This study has several limitations. First, these ML models need to be re-fitted to different 461 variables and populations to ensure accuracy across various settings. Second, the relatively small dataset 462 increases the risk of overfitting, potentially affecting the models' robustness and generalizability. Third, 463 the prevalence of DENV-1 cases from the 2012-2013 outbreak may limit the models' applicability to 464 other periods, regions, populations, age groups, or serotypes. Fourth, the models were developed using 465 data from the SEDSS, where inclusion criteria required febrile illness, potentially limiting generalizability 466 to broader populations. Fifth, due to limited sample sizes for serotypes and immune statuses, we could not 467 conduct ML analyses for these subgroups; future studies with larger datasets are needed to validate 468 findings. Sixth, there is a potential limitation related to the inclusion of false negatives—SEDSS cases 469 who may have later presented to a non-SEDSS facility with severe disease—although this is considered 470 unlikely given typical healthcare-seeking behaviors. Seventh, the SEDSS data's robustness may not 471 accurately reflect real-world conditions, where datasets are often sparse, contain free-text fields, or have 472 incomplete information, potentially affecting model performance. Eighth, dengue and severe dengue are 473 often underdiagnosed and underreported, which could impact model results; however, our findings likely 474 represent a conservative estimate when accounting for underreporting. Finally, implementing ML models 475 in clinical practice may require computational resources and infrastructure not available in all settings, 476 particularly in low-resource environments where dengue is endemic. 477 478 Conclusions

Although traditional warning signs are essential in clinical practice, their low specificity often
leads to high hospitalization rates, potentially overwhelming healthcare systems. Our findings suggest
that ML models, particularly gradient boosting algorithms, offer a more effective approach by integrating

- 482 multiple variables and capturing complex interactions, thereby improving specificity while maintaining
- 483 sensitivity. Implementing these models in clinical decision-making could help identify patients at highest
- 484 risk for progression to severe dengue, reducing unnecessary hospitalizations and easing healthcare
- 485 burdens. Although resource constraints may limit direct ML implementation in some settings, platforms
- 486 like SEDSS can still leverage ML techniques to identify key predictors of severe disease. This approach
- 487 can optimize patient care by prioritizing the most critical predictors, even in low-resource environments
- 488 where advanced ML algorithms may not be feasible.
- 489

490 Abbreviations

- 491 AdaBoost: Adaptive Boosting
- 492 AFI: acute febrile illness
- 493 ANN: Artificial Neural Networks
- 494 AUC-ROC: area under the receiver operating characteristic curve
- 495 CatBoost: Categorical Boosting
- 496 CBC: complete blood count
- 497 CHIKV: chikungunya virus
- 498 CSPF: convalescent sample processing form
- 499 CEMI: Centro de Emergencia y Medicina Integrada
- 500 CIF: case investigation form
- 501 CMESL: Centro Médico Episcopal San Lucas
- 502 DT: Decision Trees
- 503 ELISA: enzyme-linked immunosorbent assay
- 504 HESL: Hospital Episcopal San Lucas
- 505 KNN: K-Nearest Neighbors
- 506 LightGBM: Light Gradient Boosting Machine
- 507 LR: logistic regression

- 508 ML: machine learning
- 509 NPV: negative predictive value
- 510 PPV: positive predictive value
- 511 RT-PCR: reverse transcription polymerase chain reaction
- 512 SEDSS: Sentinel Enhanced Dengue Surveillance System
- 513 SHAP: SHapley Additive exPlanations
- 514 SVM: Support Vector Machines
- 515 XGBoost: eXtreme Gradient Boosting
- 516 WHO: World Health Organization

517 Declarations

- 518 **Ethics approval and consent to participate:** The Institutional Review Boards at the Centers for Disease
- 519 Control and Prevention (CDC), Auxilio Mutuo, and Ponce Medical School Foundation approved the
- 520 SEDSS study protocols 6214, and 120308-VR/2311173707, respectively. Written consent to participate
- 521 was obtained from all adult participants and emancipated minors. For minors aged 14 to 20 years, written
- 522 consent was obtained, and for those aged 7 to 13 years, parental written consent and participant assent
- 523 were obtained.
- 524 **Consent for publication:** Not applicable.
- 525 Availability of data and materials: Data cannot be shared publicly because data cannot be deidentified
- at the granular level of analyses performed. Data are available from the CDC management team (contact:
- 527 dengue@cdc.gov) for researchers who meet the criteria for access to confidential data.
- 528 **Competing interests:** The authors declare no conflict of interests.
- 529 **Funding**: This research was funded by Centers for Disease Control and Prevention, grant
- 530 numbers U01CK000473 and U01CK000580 (VRA).
- 531 **Authors' contributions:** Conception and design of the study: ZJM, MBT, and JMW. Acquisition of data:
- 532 VR. Analysis and interpretation of data: ZJM. Drafting the article: ZJM. Revising the article critically for
- 533 important intellectual content: ZJM, DR, MBT, VR, GP, LEA, and JMW. All authors have made
- substantial contributions to the study. All authors read and approved the final manuscript.
- 535 Acknowledgements: Not applicable.
- 536 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
- represent the official position of the US Centers for Disease Control and Prevention.

538 References

- 539 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS,
- 540 Hoen AG, Sankoh O *et al*: **The global distribution and burden of dengue**. *Nature* 2013,
- **496**(7446):504-507.
- 542 2. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195
- 543 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease
- 544 **Study 2017**. *Lancet* 2018, **392**(10159):1736-1788.
- 545 3. Ryff KR, Rivera A, Rodriguez DM, Santiago GA, Medina FA, Ellis EM, Torres J, Pobutsky A,
- 546 Munoz-Jordan J, Paz-Bailey G, Adams LE: **Epidemiologic Trends of Dengue in U.S.**
- 547 **Territories, 2010-2020**. *MMWR Surveill Summ* 2023, **72**(4):1-12.
- 548 4. Thayer MB, Marzan-Rodriguez M, Torres Aponte J, Rivera A, Rodriguez DM, Madewell ZJ,
- 549 Rysava K, Paz-Bailey G, Adams LE, Johansson MA: Dengue epidemic alert thresholds: A tool
 550 for surveillance and epidemic detection. *medRxiv* 2024:2024.2010.2022.24315684.
- 551 5. WHO Guidelines Approved by the Guidelines Review Committee. In: Dengue: Guidelines for
- 552 Diagnosis, Treatment, Prevention and Control: New Edition. edn. Geneva: World Health
- 553 Organization, Copyright © 2009, World Health Organization.; 2009.
- 554 6. Ahmad MH, Ibrahim MI, Mohamed Z, Ismail N, Abdullah MA, Shueb RH, Shafei MN: The
- sensitivity, specificity and accuracy of warning signs in predicting severe dengue, the severe
- 556 **dengue prevalence and its associated factors**. International Journal of Environmental Research
- 557 *and Public Health* 2018, **15**(9):2018.
- 558 7. Narvaez F, Gutierrez G, Pérez MA, Elizondo D, Nuñez A, Balmaseda A, Harris E: Evaluation of
 559 the traditional and revised WHO classifications of dengue disease severity. *PLoS neglected*
- 560 *tropical diseases* 2011, **5**(11):e1397.
- 561 8. Macedo GA, Gonin MLC, Pone SM, Cruz OG, Nobre FF, Brasil P: Sensitivity and specificity of
- 562 the World Health Organization dengue classification schemes for severe dengue assessment
- 563 **in children in Rio de Janeiro**. *PloS one* 2014, **9**(4):e96314.

564	9.	Jayaratne SD, Atukorale V, Gomes L, Chang T, Wijesinghe T, Fernando S, Ogg GS, Malavige
565		GN: Evaluation of the WHO revised criteria for classification of clinical disease severity in
566		acute adult dengue infection. BMC Res Notes 2012, 5:645.
567	10.	Thein TL, Gan VC, Lye DC, Yung CF, Leo YS: Utilities and limitations of the World Health
568		Organization 2009 warning signs for adult dengue severity. PLoS Negl Trop Dis 2013,
569		7 (1):e2023.
570	11.	Hoyos W, Aguilar J, Toro M: Dengue models based on machine learning techniques: A
571		systematic literature review. Artificial Intelligence in Medicine 2021, 119:102157.
572	12.	Gupta G, Khan S, Guleria V, Almjally A, Alabduallah BI, Siddiqui T, Albahlal BM, Alajlan SA,
573		Al-Subaie M: DDPM: A Dengue Disease Prediction and Diagnosis Model Using Sentiment
574		Analysis and Machine Learning Algorithms. <i>Diagnostics (Basel)</i> 2023, 13(6).
575	13.	Tomashek KM, Rivera A, Torres-Velasquez B, Hunsperger EA, Munoz-Jordan JL, Sharp TM,
576		Rivera I, Sanabria D, Blau DM, Galloway R et al: Enhanced Surveillance for Fatal Dengue-
577		Like Acute Febrile Illness in Puerto Rico, 2010-2012. PLoS Negl Trop Dis 2016,
578		10 (10):e0005025.
579	14.	Madewell ZJ, Hernandez-Romieu AC, Wong JM, Zambrano LD, Volkman HR, Perez-Padilla J,
580		Rodriguez DM, Lorenzi O, Espinet C, Munoz-Jordan J et al: Sentinel Enhanced Dengue
581		Surveillance System - Puerto Rico, 2012-2022. MMWR Surveill Summ 2024, 73(3):1-29.
582	15.	Read JS, Torres-Velasquez B, Lorenzi O, Rivera Sanchez A, Torres-Torres S, Rivera LV, Capre-
583		Franceschi SM, Garcia-Gubern C, Munoz-Jordan J, Santiago GA, Alvarado LI: Symptomatic
584		Zika Virus Infection in Infants, Children, and Adolescents Living in Puerto Rico. JAMA
585		<i>Pediatr</i> 2018, 172 (7):686-693.
586	16.	Wong JM, Volkman HR, Adams LE, García CO, Martinez-Quiñones A, Perez-Padilla J, Bertrán-
587		Pasarell J, de la Pena DS, Tosado-Acevedo R, Santiago GA: Clinical Features of COVID-19,
588		Dengue, and Influenza among Adults Presenting to Emergency Departments and Urgent

589 **Care Clinics—Puerto Rico, 2012–2021**. *The American Journal of Tropical Medicine and*

- 590 *Hygiene* 2023, **108**(1):107.
- 591 17. Handbook for clinical management of dengue
- 592 [https://www.who.int/publications/i/item/9789241504713]
- 593 18. Paz-Bailey G, Sánchez-González L, Torres-Velasquez B, Jones ES, Perez-Padilla J, Sharp TM,
- 594 Lorenzi O, Delorey M, Munoz-Jordan JL, Tomashek KM et al: Predominance of Severe Plasma
- 595 Leakage in Pediatric Patients With Severe Dengue in Puerto Rico. The Journal of Infectious
- 596 *Diseases* 2022, **226**(11):1949-1958.
- 19. eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses [https://cran.r-
- 598 project.org/web/packages/eulerr/index.html]
- 599 20. Tomashek KM, Lorenzi OD, Andújar-Pérez DA, Torres-Velásquez BC, Hunsperger EA, Munoz-
- Jordan JL, Perez-Padilla J, Rivera A, Gonzalez-Zeno GE, Sharp TM *et al*: Clinical and
- 601 epidemiologic characteristics of dengue and other etiologic agents among patients with
- 602 **acute febrile illness, Puerto Rico, 2012-2015**. *PLoS Negl Trop Dis* 2017, **11**(9):e0005859.
- 603 21. Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K: Clinical
- predictors of severe dengue: a systematic review and meta-analysis. *Infect Dis Poverty* 2021,
 10(1):123.
- 606 22. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, Dorigatti I,
- Holmes A: Risk predictors of progression to severe disease during the febrile phase of
 dengue: a systematic review and meta-analysis. *Lancet Infect Dis* 2021, 21(7):1014-1026.
- 609 23. Khan MAS, Al Mosabbir A, Raheem E, Ahmed A, Rouf RR, Hasan M, Alam FB, Hannan N,
- 610 Yesmin S, Amin R *et al*: Clinical spectrum and predictors of severity of dengue among
- 611 children in 2019 outbreak: a multicenter hospital-based study in Bangladesh. BMC Pediatr
- 612 2021, **21**(1):478.
- Yuan K, Chen Y, Zhong M, Lin Y, Liu L: Risk and predictive factors for severe dengue
 infection: A systematic review and meta-analysis. *PLoS One* 2022, 17(4):e0267186.

- 615 25. Werner de Vargas V, Schneider Aranda JA, Dos Santos Costa R, da Silva Pereira PR, Victória
- Barbosa JL: **Imbalanced data preprocessing techniques for machine learning: a systematic**
- 617 mapping study. *Knowl Inf Syst* 2023, 65(1):31-57.
- 618 26. caret: Classification and Regression Training [https://cran.r-
- 619 project.org/web/packages/caret/index.html]
- 620 27. MASS: Support Functions and Datasets for Venables and Ripley's MASS [https://cran.r-
- 621 project.org/web/packages/MASS/index.html]
- 622 28. Kotsiantis SB: Decision trees: a recent overview. Artificial Intelligence Review 2013, 39:261-
- 623 283.
- 624 29. Peterson LE: K-nearest neighbor. *Scholarpedia* 2009, 4(2):1883.
- Webb GI, Keogh E, Miikkulainen R: Naïve Bayes. *Encyclopedia of machine learning* 2010,
 15(1):713-714.
- Hearst MA, Dumais ST, Osuna E, Platt J, Scholkopf B: Support vector machines. *IEEE Intelligent Systems and their applications* 1998, 13(4):18-28.
- 629 32. Aggarwal CC: Neural networks and deep learning, vol. 10: Springer; 2018.
- 63033.Schapire RE: The boosting approach to machine learning: An overview. Nonlinear estimation
- 631 *and classification* 2003:149-171.
- Bentéjac C, Csörgő A, Martínez-Muñoz G: A comparative analysis of gradient boosting
 algorithms. *Artificial Intelligence Review* 2021, 54:1937-1967.
- 634 35. Khan AA, Chaudhari O, Chandra R: A review of ensemble learning and data augmentation
- 635 models for class imbalanced problems: Combination, implementation and evaluation.
- *Expert Systems with Applications* 2024, **244**:122778.
- 637 36. rpart: Recursive Partitioning and Regression Trees [https://cran.r-
- 638 project.org/web/packages/rpart/index.html]
- 639 37. e1071: Misc Functions of the Department of Statistics, Probability Theory Group
- 640 (Formerly: E1071), TU Wien [https://cran.r-project.org/web/packages/e1071/index.html]

- 641 38. nnet: Feed-Forward Neural Networks and Multinomial Log-Linear Models [https://cran.r-
- 642 project.org/web/packages/nnet/index.html]
- 643 39. keras: R Interface to 'Keras' [https://cran.r-project.org/web/packages/keras/index.html]
- 644 40. ada: The R Package Ada for Stochastic Boosting [https://cran.r-
- 645 project.org/web/packages/ada/index.html]
- 41. Prokhorenkova L, Gusev G, Vorobev A, Dorogush AV, Gulin A: CatBoost: unbiased boosting
- 647 with categorical features. Advances in neural information processing systems 2018, 31.
- 648 42. lightgbm: Light Gradient Boosting Machine [https://cran.r-
- 649 <u>project.org/web/packages/lightgbm/index.html]</u>
- 650 43. xgboost: Extreme Gradient Boosting [https://cran.r-
- 651 project.org/web/packages/xgboost/index.html]
- 652 44. **R: A language and environment for statistical computing.**
- 45. Wickham H: ggplot2. Wiley interdisciplinary reviews: computational statistics 2011, 3(2):180185.
- 46. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more
- 656 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*657 1988, 44(3):837-845.
- 1700, 44(3).037-045.
- 47. Lee IK, Huang CH, Huang WC, Chen YC, Tsai CY, Chang K, Chen YH: Prognostic Factors in
- Adult Patients with Dengue: Developing Risk Scoring Models and Emphasizing Factors
- 661 *Med* 2018, **7**(11).
- 48. Wakimoto MD, Camacho LA, Guaraldo L, Damasceno LS, Brasil P: Dengue in children: a
- 663 systematic review of clinical and laboratory factors associated with severity. Expert Rev Anti
- 664 Infect Ther 2015, **13**(12):1441-1456.

665	49.	Sami CA, Tasnim R, Hassan SS, Khan AH, Yasmin R, Monir-Uz-Zaman M, Sarker MAS, Arafat
666		SM: Clinical profile and early severity predictors of dengue fever: Current trends for the
667		deadliest dengue infection in Bangladesh in 2022. IJID Reg 2023, 9:42-48.
668	50.	Ming DK, Hernandez B, Sangkaew S, Vuong NL, Lam PK, Nguyet NM, Tam DTH, Trung DT,
669		Tien NTH, Tuan NM: Applied machine learning for the risk-stratification and clinical
670		decision support of hospitalised patients with dengue in Vietnam. PLOS digital health 2022,
671		1 (1):e0000005.
672	51.	Ong SQ, Isawasan P, Ngesom AMM, Shahar H, Lasim AmM, Nair G: Predicting dengue
673		transmission rates by comparing different machine learning models with vector indices and
674		meteorological data. Scientific reports 2023, 13(1):19129.
675	52.	Madewell ZJ, Rodriguez DM, Thayer MB, Rivera-Amill V, Torres Aponte J, Marzan-Rodriguez
676		M, Paz-Bailey G, Adams LE, Wong JM: Machine learning for improved dengue diagnosis,
677		Puerto Rico. medRxiv 2024:2024.2011.2013.24317272.
678	53.	Chaw JK, Chaw SH, Quah CH, Sahrani S, Ang MC, Zhao Y, Ting TT: A predictive analytics
679		model using machine learning algorithms to estimate the risk of shock development among
680		dengue patients. Healthcare Analytics 2024, 5:100290.
681	54.	Liu YE, Saul S, Rao AM, Robinson ML, Agudelo Rojas OL, Sanz AM, Verghese M, Solis D,
682		Sibai M, Huang CH et al: An 8-gene machine learning model improves clinical prediction of
683		severe dengue progression. Genome Med 2022, 14(1):33.
684	55.	Hung SJ, Tsai HP, Wang YF, Ko WC, Wang JR, Huang SW: Assessment of the Risk of Severe
685		Dengue Using Intrahost Viral Population in Dengue Virus Serotype 2 Patients via Machine
686		Learning. Front Cell Infect Microbiol 2022, 12:831281.
687	56.	Cramer EY, Ray EL, Lopez VK, Bracher J, Brennen A, Castro Rivadeneira AJ, Gerding A,
688		Gneiting T, House KH, Huang Y et al: Evaluation of individual and ensemble probabilistic
689		forecasts of COVID-19 mortality in the United States. Proc Natl Acad Sci U S A 2022,
690		119 (15):e2113561119.

- 691 57. Dean NE, Pastore YPA, Madewell ZJ, Cummings DAT, Hitchings MDT, Joshi K, Kahn R,
- 692 Vespignani A, Halloran ME, Longini IM, Jr.: Ensemble forecast modeling for the design of
- 693 **COVID-19 vaccine efficacy trials**. *Vaccine* 2020, **38**(46):7213-7216.
- 58. Ho TS, Weng TC, Wang JD, Han HC, Cheng HC, Yang CC, Yu CH, Liu YJ, Hu CH, Huang CY
- 695 *et al*: **Comparing machine learning with case-control models to identify confirmed dengue**
- 696 **cases**. *PLoS Negl Trop Dis* 2020, **14**(11):e0008843.

698 Figure Titles and Legends

- **Figure 1**. Euler plot of proportion of severe dengue cases with each warning sign, Sentinel Enhanced
- 700 Dengue Surveillance System, Puerto Rico, 2012–2024.
- Figure 2. Pearson's correlation of predictions between machine learning models, Sentinel Enhanced
- 702 Dengue Surveillance System, Puerto Rico, 2012–2024. Pearson correlation coefficients measure the linear
- agreement between the predictions of different machine learning models. Higher values indicate similar
- prediction patterns across models, suggesting that models are identifying similar cases as severe dengue.
- 705 Darker colors represent higher correlations.
- **Figure 3**. Forest plot of AUC values for Decision Trees (DT), K-Nearest Neighbors (KNN), Naïve Bayes,
- 707 Support Vector Machines (SVM), Artificial Neural Networks (ANN), Adaptive Boosting (AdaBoost),
- 708 Categorical Boosting (CatBoost), Light Gradient Boosting Machine (LightGBM), eXtreme Gradient
- 709 Boosting (XGBoost), and ensemble models for a 40-variable feature set and subsets excluding CBCs,
- 710 IgG, and serotype results, Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024.
- 711 DeLong method was used to obtain the 95% confidence intervals for the AUC-ROC. CBC = complete
- blood count, IgG = immunoglobulin G, AUC-ROC = area under the receiver operating characteristic
- 713 curve.
- **Figure 4.** SHapley Additive exPlanations (SHAP) values for the 40 Features in CatBoost, Sentinel
- 715 Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024. SHAP values measure each feature's
- contribution to the prediction of severe dengue in the CatBoost model. Positive SHAP values indicate a
- 717 higher likelihood of severe dengue, while negative values suggest a lower likelihood (or protective
- reflect). Each dot represents a single case, with its horizontal position showing the SHAP value, reflecting
- the strength and direction of the feature's impact. The color of the dots indicates the actual feature value
- for each case. For most features, values are binary (0 or 1), representing presence or absence (e.g., rash or
- no rash). For age group, the scale ranges from 0 to 7, with 0 indicating the youngest age group (<1 year)
- and 7 indicating the oldest age group (\geq 50 years). An example interpretation: if 'persistent vomiting' has
- a positive SHAP value and the dot is green (value = 1), it indicates that the presence of persistent

- vomiting strongly increases the likelihood of severe dengue for that case. The mean SHAP values shown
- on the right represent the average absolute impact of each feature across all cases, indicating the overall
- importance of that feature in the model's predictions.
- 727 Figure 5. Iterative improvement in area under the curve (AUC) with additional variables in CatBoost
- model for severe dengue prediction, Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–
- 729 2024. This figure shows the change in AUC as top-performing variables are sequentially added to the
- 730 CatBoost model. Starting with the highest-impact feature, "Days post onset," each subsequent model
- includes one additional variable in the order of their mean SHAP values. The combinations of variables
- and their AUC, along with 95% confidence intervals, are shown to demonstrate the predictive gain with
- each added variable.

ELICA by sevency; centilier Enhanced Denga	Total	Severe dengue	Not covere	
	1 OLA N - 1 702	Severe deligue	NOL SEVELE	
	n (column %)	n (column %)	n (column %)	n-value
Davs nost onset				<0.001
n	128 (7 5)	18 (4 3)	110 (8 5)	0.001
1_3	810 (17.4)	133 (32 0)	677 (52 /)	
1.6	605 (40 7)	243 (58.6)	452 (35 0)	
4-0 7_	75 (4 4)	243 (30.0)	402 (00.0) 54 (4 2)	
	75 (4.4)	21 (3.1)	J4 (4,2)	<0.001
	32 (1 0)	5 (1 2)	27 (2 1)	10,001
1 /	109 (6.4)	11 (2 7)	08 (7 6)	
5.0	238 (13 0)	12 (10 1)	106 (15 2)	
10.10	230 (13.9)	42 (10.1)	130 (13.2)	
20.20	004 (40.0)	214 (31.0)	470 (30.3)	
20-29	225 (15.2)	30 (9.2) 27 (6.5)	01 (7 0)	
30-39 40 40	02 (5 4)	27 (0.5)	91 (7.0) 72 (F.G)	
40-49	93 (3.4) 200 (12.2)	20 (4.0)	151 (3.0)	
50+ Formala any	209 (12.2)	30 (14.U) 195 (44.C)	IOI (II.7) 647 (477)	0.200
	00Z (47.0)	165 (44.6)	017 (47.7)	~0.001
DENV IMmune status	E77 (22 0)	400 (42 4)	207 (20 7)	<0.001
Post-primary	577 (33.8) 152 (0.0)	180 (43.4)	397 (30.7)	
	153 (9.0)	30(7.2)	123 (9.5)	
	978 (57.3)	205 (49.4)	773 (59.8)	<0.001
DENV Serotype	005 (50 0)			<0.001
1	905 (53.0)	226 (54.5)	679 (52.5)	
2	102 (6.0)	15 (3.6)	87 (0.7)	
3	149 (8.7)	18 (4.3)	131 (10.1)	
4	50 (2.9)	19 (4.6)	31 (2.4)	
Unknown	502 (29.4)	137 (33.0)	365 (28.2)	
Comorbidities	047 (00.0)	70 (10 0)	074 (04 0)	0.070
Chronic pulmonary disease or asthma	347 (20.3)	76 (18.3)	271 (21.0)	0.273
Cancer	27 (1.6)	6 (1.4)	21 (1.6)	0.978
Chronic kidney disease	12 (0.7)	5 (1.2)	7 (0.5)	0.285
Coronary heart disease	52 (3.0)	16 (3.9)	36 (2.8)	0.347
Diabetes	108 (6.3)	29 (7.0)	/9 (6.1)	0.601
High cholesterol	84 (4.9)	24 (5.8)	60 (4.6)	0.420
Hypertension	156 (9.1)	41 (9.9)	115 (8.9)	0.611
Arthritis	23 (1.3)	5 (1.2)	18 (1.4)	0.965
Thyroid disease	74 (4.3)	16 (3.9)	58 (4.5)	0.682
Obesity	214 (12.5)	43 (10.4)	171 (13.2)	0.148
Gastritis	28 (1.6)	9 (2.2)	19 (1.5)	0.451
Warning signs				/
Persistent vomiting	420 (24.6)	156 (37.6)	264 (20.4)	< 0.001
Abdominal pain	995 (58.3)	328 (79.0)	667 (51.6)	<0.001
Restlessness	797 (46.7)	268 (64.6)	529 (40.9)	<0.001
Mucosal bleeding	274 (16.0)	95 (22.9)	179 (13.8)	<0.001
Hemoconcentration	129 (7.6)	86 (20.7)	43 (3.3)	<0.001
Hepatomegaly	47 (2.8)	19 (4.6)	28 (2.2)	0.015
Other clinical signs/symptoms				
Fever	1695 (99.2)	412 (99.3)	1283 (99.2)	1.000

Table 1. Demographic and clinical characteristics of participants with laboratory-confirmed dengue (RT-PCR and IgM ELISA) by severity. Sentinel Enhanced Dengue Surveillance System. Puerto Rico. 2012–2024.

Chills 1362 (79.7) 369 (88.9) 993 (76.8) <	0.001 0.001 0.001
Nausea 1175 (68.8) 333 (80.2) 842 (65.1) <	0.001 0.001
	0.001
No appetite 1330 (77.9) 363 (87.5) 967 (74.8) <	
Rash 971 (56.9) 286 (68.9) 685 (53.0) <	0.001
Yellow skin 69 (4.0) 36 (8.7) 33 (2.6) <	0.001
ltchy skin 627 (36.7) 190 (45.8) 437 (33.8) <	0.001
Bruise 103 (6.0) 35 (8.4) 68 (5.3)	0.025
He adache 1432 (83.8) 372 (89.6) 1060 (82.0) <	0.001
Eye pain 1026 (60.1) 288 (69.4) 738 (57.1) <	0.001
Myalgia 1276 (74.7) 362 (87.2) 914 (70.7) <	0.001
Arthralgia 1062 (62.2) 301 (72.5) 761 (58.9) <	0.001
Back pain 912 (53.4) 261 (62.9) 651 (50.3) <	0.001
Calf pain 627 (36.7) 180 (43.4) 447 (34.6) <	0.001
Arthritis 251 (14.7) 84 (20.2) 167 (12.9) <	0.001
Nasal discharge 545 (31.9) 149 (35.9) 396 (30.6)	0.052
Sore throat 615 (36.0) 168 (40.5) 447 (34.6)	0.034
Cough 726 (42.5) 189 (45.5) 537 (41.5)	0.167
Diarrhea 736 (43.1) 228 (54.9) 508 (39.3) <	0.001
Seizure 30 (1.8) 30 (7.2) 0 (0.0) <	0.001
Pale skin 783 (45.8) 266 (64.1) 517 (40.0) <	0.001
Blue lips 72 (4.2) 35 (8.4) 37 (2.9) <	0.001
Laboratory	
Leukopenia 1012 (59.3) 320 (77.1) 692 (53.5) <	0.001

p-values were calculated using either the chi-square test or Fisher's exact test, as appropriate, based on the sample sizes in each category.

735

True True False False Positive Negative									
	Positive	Negative	Positive	Negative	Sensitivity	Specificity	Predictive Value	Predictive Value	AUC-ROC
Warning sign	n (%)	n (%)	n (%)	n (%)	% (95% CÍ)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Persistent vomiting	156 (9.1)	1029 (60.2)	264 (15.5)	259 (15.2)	37.6 (32.9, 42.4)	79.6 (77.3, 81.7)	37 1 (32 5, 42 0)	79.9 (77.6, 82.0)	58.5 (56.0, 61.1)
Abdominal pain	328 (19.2)	626 (36.7)	667 (39.1)	87 (5.1)	79.0 (74.8, 82.9)	48.4 (45.7, 51.2)	33.0 (30.0, 36.0)	87 8 (85 2, 90 1)	60.4 (58.5, 62.3)
Restlessness	268 (15.7)	764 (44.7)	529 (31.0)	147 (8.6)	64 6 (59 8, 69 2)	59 1 (56 4, 61 8)	33.6 (30.3, 37.0)	83.9 (81.3, 86.2)	58.7 (56.7, 60.8)
Mucosal bleeding	95 (5.6)	1114 (65.2)	179 (10.5)	320 (18.7)	22.9 (18.9, 27.2)	86 2 (84 2, 88 0)	34.7 (29.0, 40.6)	77.7 (75.4, 79.8)	56.2 (53.2, 59.2)
Hemoconcentration	86 (5.0)	1250 (73.2)	43 (2.5)	329 (19.3)	20 7 (16 9, 24 9)	96 7 (95 5, 97 6)	66 7 (57 8, 74 7)	79.2 (77.1, 81.1)	72.9 (68.7, 77.1)
Hepatomegaly	19 (1.1)	1265 (74.1)	28 (1.6)	396 (23.2)	4.6 (2.8, 7.1)	97 8 (96 9, 98 6)	40 4 (26 4, 55 7)	76.2 (74.0, 78.2)	58.3 (51.1, 65.5)
Any warning sign	388 (22.7)	347 (20.3)	946 (55.4)	27 (1.6)	93 5 (90 7, 95 7)	26.8 (24.4, 29.3)	29 1 (26 7, 31 6)	92.8 (89.7, 95.2)	60.9 (59.1, 62.7)
Only one warning sign	78 (9.0)	347 (40.1)	413 (47.7)	27 (3.1)	74 3 (64 8, 82 3)	45 7 (42 1, 49 3)	15.9 (12.8, 19.4)	92.8 (89.7, 95.2)	54.3 (52.2, 56.4)
Only two warning signs	126 (14.9)	347 (41.0)	347 (41.0)	27 (3.2)	82.4 (75.4, 88.0)	50 0 (46 2, 53 8)	26.6 (22.7, 30.9)	92.8 (89.7, 95.2)	59 7 (57 3, 62 1)
Three or more warning signs	184 (24.7)	347 (46.6)	186 (25.0)	27 (3.6)	87 2 (81 9, 91 4)	65 1 (60 9, 69 2)	497 (445, 549)	92.8 (89.7, 95.2)	71.3 (68.4, 74.1)

Table 2. Performance of warning signs for predicting severe dengue (n=1708), Sentinel Enhanced Dengue Surveillance System, Puerto Rico, 2012–2024.

AUC-ROC: area under receiver operating characteristic curve.



KNN -	0.58												
DT -	0.65	0.60											
LR -	0.78	0.71	0.76										
SVM -	0.79	0.67	0.75	0.94							Corre	elatio	n
ANN -	0.56	0.65	0.61	0.70	0.70							0.9 0.8	
Adaboost -	0.63	0.68	0.66	0.75	0.73	0.85						0.7	
.ightGBM -	0.58	0.64	0.63	0.69	0.67	0.83	0.96					0.6 0.5	
XGBoost -	0.59	0.64	0.63	0.68	0.66	0.82	0.96	0.98					
CatBoost -	0.56	0.66	0.62	0.68	0.66	0.83	0.93	0.95	0.95				
insemble -	0.48	0.48	0.51	0.55	0.54	0.75	0.84	0.89	0.89	0.91			
	Naive.Bayes	KNN	DT	LR	SVM	ANN	Adaboost	LightGBM	XGBoost	CatBoost			

1

I







Variable Combinations